Morgan Stanley Cuts Biogen (NASDAQ:BIIB) Price Target to $157.00

Biogen (NASDAQ:BIIB – Free Report) had its target price reduced by Morgan Stanley from $192.00 to $157.00 in a report published on Thursday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock. Several other equities analysts have also commented on BIIB. Piper Sandler lowered Biogen from an “overweight” rating […]